StockNews.com Initiates Coverage on BIOLASE (NASDAQ:BIOL)

Research analysts at StockNews.com began coverage on shares of BIOLASE (NASDAQ:BIOL) in a research report issued to clients and investors on Tuesday. The brokerage set a “sell” rating on the medical technology company’s stock.

BIOL has been the subject of several other research reports. Ascendiant Capital Markets decreased their price objective on shares of BIOLASE from $3.50 to $2.00 and set a “buy” rating for the company in a research note on Tuesday, September 3rd. Benchmark restated a “speculative buy” rating and issued a $0.40 price objective on shares of BIOLASE in a research note on Wednesday, October 2nd.

BIOLASE Price Performance

NASDAQ BIOL opened at $0.00 on Tuesday. BIOLASE has a 1 year low of $0.02 and a 1 year high of $1.94. The company has a market capitalization of $133,628.00, a PE ratio of 0.00 and a beta of 0.67. The company has a fifty day moving average of $0.03 and a two-hundred day moving average of $0.08.

Institutional Investors Weigh In On BIOLASE

A hedge fund recently raised its stake in BIOLASE stock. Virtu Financial LLC lifted its holdings in shares of BIOLASE, Inc. (NASDAQ:BIOL) by 1,068.0% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The firm owned 143,537 shares of the medical technology company’s stock after buying an additional 131,248 shares during the period. Virtu Financial LLC owned approximately 0.43% of BIOLASE worth $27,000 at the end of the most recent quarter. Institutional investors own 8.79% of the company’s stock.

About BIOLASE

BIOLASE, Inc, together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. Its dental laser systems allow dentists, periodontists, endodontists, pediatric dentists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, including cosmetic, restorative, and complex surgical applications.